We found one randomised study comparing oral etoposide with vinblastine in the treatment of classical KS in elderly Mediterranean patients.46 We found no randomised evidence for the use of single-agent vinca alkaloids in AIDS-related KS. Several uncontrolled phase II studies used single-agent vinblastine in the treatment of both classical and AIDS-related KS.2547-52
In one study, 65 elderly patients with classical KS were randomised between oral etoposide and intravenous vinblastine.46 Etoposide was given every 3 weeks at a dose of 60 mg/m2 on days 1-3 for the first cycle, days 1-4 for the second cycle and days 1-5 for the third cycle. Vinblastine was given intravenously at a dose of 3 mg/m2 weekly for the first 3 weeks then 6 mg/m2 every 3 weeks. The overall response rate was 73% for etoposide and 58% for vinblastine (P = 0-3). An uncontrolled phase II study of single-agent vinblastine in 38 patients with AIDS-related KS reported an overall response rate of 26% with weekly vinblastine, 4-8 mg/week titrated against white blood cell count.49 Reported response rates to vinblastine in small uncontrolled studies are higher for classical KS than for AIDS-related KS.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.